DRTS Stock Analysis: Buy, Sell, or Hold?
DRTS - Alpha Tau Medical Ltd. Ordinary Shares
$8.51
0.66 (8.41%)
▲
5d:
-0.35%
30d:
+15.78%
90d:
+19.69%
BUY
HIGH Confidence
Analysis Updated: May 8, 2026 12:00 AM ET
Earnings: May 18, 2026
6d
Smart Money Accumulation
DRTS is down 3.1% this week, but smart money is accumulating calls. Top strike: $10 2026-06-18 with 390 OI. Call ratio: 100% View Scanner →
Strength: 6.6/10
Get Alerted When DRTS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
15 traders called DRTS this week
98% bullish • 3 bearish
98% bullish • 3 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: DRTS shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: DRTS shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: DRTS is currently trading at $8.51, which is considered fair relative to its 30-day fair value range of $7.05 to $8.07.
Technical Outlook: Technically, DRTS is in a strong uptrend. Immediate support is located at $7.15, while resistance sits at $9.07. The stock is showing strong short-term momentum, up 8.4% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $9.50 (+11.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DRTS is in a strong uptrend. Immediate support is located at $7.15, while resistance sits at $9.07. The stock is showing strong short-term momentum, up 8.4% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $9.50 (+11.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$7.05 -
$8.07
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+8.4%)
- BULLISH: Trading below Wall St target ($9.50)
Trading Range Analysis
30-Day Trading Range
$7.05 -
$8.07
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$7.15
Resistance Level
$9.07
Current Trend
Strong Uptrend
Technical data as of
May 8, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-19.99
Wall Street Target
$9.50
(+11.6%)
Share & Embed Analysis
Last updated: May 11, 2026 7:05 AM ET
Data refreshes hourly during market hours. Next update: 8:05 AM
Data refreshes hourly during market hours. Next update: 8:05 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DRTS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 58 HOLD |
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 53 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 65 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$270 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$109 | 62 BUY |
